5/9/2025

The big pharma will spend up to $250 million over the next eight years of the collaboration. Elsewhere, CRISPR Therapeutics unveiled new data and Vivo Capital raised funds.

Source: Yahoo

5/8/2025

Charles River Laboratories International Inc. stock outperforms competitors on strong trading day

Source: MarketWatch

5/8/2025

Charles River Laboratories International, Inc. ( NYSE:CRL ), is not the largest company out there, but it received a...

Source: Yahoo

5/8/2025

Despite a dip in revenue, Charles River Laboratories International Inc (CRL) boosts earnings per share and strengthens its position in preclinical drug development.

Source: Yahoo

5/7/2025

The S&P 500 rose 0.4% on Wednesday, May 7, 2025, as investors reviewed the details of today’s Federal Reserve meeting and parsed comments by President Donald Trump on trade with China.

Source: Yahoo

5/7/2025

Investing.com -- Charles River Laboratories (NYSE:CRL) announced Wednesday it will appoint four new directors to its board and launch a comprehensive strategic review following a cooperation agreement with activist hedge fund Elliott Investment Management, the company’s largest shareholder. The changes will be overseen by a newly formed Strategic Planning and Capital Allocation Committee aimed at enhancing long-term shareholder value.

Source: Yahoo

5/7/2025

Shares of lab services company Charles River Laboratories (NYSE:CRL) jumped 17.3% in the afternoon session after the company reported strong first quarter 2025 results which significantly beat analysts' organic revenue and EPS estimates, and featured a raise to full-year EPS guidance. Zooming out, we think this was a solid print.

Source: Yahoo

5/7/2025

The biotech said its largest investor would conduct a “strategic review” as revenue continued to decline.

Source: Yahoo

5/7/2025

U.S. equities were little changed at midday with the market focused on comments from the Federal Reserve coming later today.

Source: Yahoo

5/7/2025

Charles River Laboratories International, Inc. (NYSE:CRL) Q1 2025 Results Conference Call May 7, 2025 9:00 AM ETCompany ParticipantsTodd Spencer - Vice...

Source: SeekingAlpha

5/7/2025

Charles River Laboratories stock surged 16% Wednesday morning as the medical testing company made changes to its board and announced a strategic review as it faced pressure from Elliott Investment Management.

Source: Yahoo

5/7/2025

Charles River delivers better-than-expected earnings and revenues in the first quarter of 2025.

Source: Yahoo

5/7/2025

The headline numbers for Charles River (CRL) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Source: Yahoo

5/7/2025

Lab services company Charles River Laboratories (NYSE:CRL) reported Q1 CY2025 results exceeding the market’s revenue expectations, but sales fell by 2.7% year on year to $984.2 million. Its non-GAAP profit of $2.34 per share was 12.8% above analysts’ consensus estimates.

Source: Yahoo

5/7/2025

Charles River (CRL) delivered earnings and revenue surprises of 13.59% and 5.25%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Source: Yahoo

5/7/2025

CRL) on Wednesday reported first-quarter profit of $25.5 million. On a per-share basis, the Wilmington, Massachusetts-based company said it had profit of 50 cents. Earnings, adjusted for one-time gains and costs, came to $2.34 per share.

Source: Yahoo

5/7/2025

WILMINGTON, Mass., May 07, 2025--Charles River Laboratories Announces First-Quarter 2025 Financial Results

Source: Yahoo

5/7/2025

WILMINGTON, Mass., May 07, 2025--Charles River Laboratories Announces Governance Updates and Strategic Review to Enhance Long-Term Stockholder Value

Source: Yahoo

5/7/2025

(Reuters) -Charles River Laboratories shares jumped 15% on Wednesday after the company raised its annual profit forecast due to improving demand for contract drug research services. Separately, the Massachusetts-based company also said that it had reached an agreement with activist investor Elliott Management. Charles River's stock climbed to $133.36, though it has fallen approximately 37% year-to-date as the company and other contract drugmakers face sluggish demand among smaller biotech companies, negatively impacting their financial performance.

Source: Yahoo

5/7/2025

Charles River Laboratories International, Inc. announced on May 7, 2025, that it had reached an agreement with activist investor Elliott Investment Management and added four new directors to its...

Source: Finnhub